ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Artiva Biotherapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$5.89+0.04 (+0.68%)

Close on Oct 19, 2026

Market cap: $232.14M
P/E (TTM): –
Dividend yield: –

Artiva Biotherapeutics, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Depreciation & Amortization	2.60	2.43	2.27
Stock-Based Compensation	6.82	6.98	7.05
Change in Accounts Receivable	0	1.03	-0.51
Change in Accounts Payable	-0.76	0.52	-0.41
Change in Unearned Revenue	–	–	-27
Operating Cash Flow	-77	-55	-47
Capital Expenditures	-2.59	-0.64	-3.26
Purchase of Investments	-45	-176	-50
Sale & Maturity of Investments	111	56	–
Investing Cash Flow	63	-120	-26
Stock Issued	0	167	–
Financing Cash Flow	0.01	162	24
Net Change in Cash	-13	-13	-49
Free Cash Flow	-79	-56	-51
Income Taxes Paid	–	0	0.08

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -56.5%

Financial strength

Current ratio: 24.16
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 2067.4%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.67
Dividend yield: –